I agree with your sentiment Risk/Dave. Good overview. Alzheimer's in General is about to become much bigger than we all think. Just my opinion. Having a diagnostic revenue product and therapeutic potential product is absolutely massive! I can see where it is nice to have a conservative estimate of .40, but glad to see you are adding a range now with a potentially higher estimate. The dots I am connecting lead me to believe the higher end. I think data, CLIA partner, and revenue guidance get us to the higher estimate. I think a BP will get involved for both Dx and Tx Alzheimer's and that is what will catapult the share price and force the uplist.